Spero Therapeutics (SPRO) Net Income Growth (1y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 12.59% |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -115.51% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 59.59% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -10.08% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -73.01% |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1,228.66% |
| 10 | Spero Therapeutics | 154.37 Mn | 98.24 Mn | - | 48.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.06% |
| Dec 31, 2025 | 230.92% |
| Sep 30, 2025 | 58.28% |
| Jun 30, 2025 | 90.46% |
| Mar 31, 2025 | -9.58% |
| Dec 31, 2024 | -143.68% |
| Sep 30, 2024 | -454.02% |
| Jun 30, 2024 | -50.01% |
| Mar 31, 2024 | 4.59% |
| Dec 31, 2023 | 100.51% |
| Sep 30, 2023 | 72.14% |
| Jun 30, 2023 | 54.15% |
| Mar 31, 2023 | 55.98% |
| Dec 31, 2022 | 200.22% |
| Sep 30, 2022 | 48.89% |
| Jun 30, 2022 | -40.68% |
| Mar 31, 2022 | -56.10% |
| Dec 31, 2021 | -46.30% |
| Sep 30, 2021 | -18.13% |
| Jun 30, 2021 | -0.38% |
| Mar 31, 2021 | 14.52% |
| Dec 31, 2020 | 26.66% |
| Sep 30, 2020 | -8.01% |
| Jun 30, 2020 | -38.43% |
| Mar 31, 2020 | -313.85% |
| Dec 31, 2019 | -140.21% |
| Sep 30, 2019 | -68.04% |
| Jun 30, 2019 | -33.44% |
| Mar 31, 2019 | 48.73% |
| Dec 31, 2018 | 23.23% |
| Sep 30, 2018 | -6.31% |
| Jun 30, 2018 | 1.55% |
| Mar 31, 2018 | -39.87% |
| Dec 31, 2017 | -57.34% |
| Sep 30, 2017 | -24.36% |